Trusted Resources: Education
Scientific literature and patient education texts
Understanding Mucopolysaccharidosis Type VII (MPS VII) or Sly Syndrome
source: Ultragenyx Pharmaceutical Inc.
year: N/A
summary/abstract:MPS VII, also called Sly syndrome, is a rare, life-threatening lysosomal storage disorder, caused by mutations of the GUSB gene, which results in a deficiency of the β-glucuronidase enzyme. β-glucuronidase plays a key role in the breakdown of glycosaminoglycans (GAGs), previously called mucopolysaccharides. The inability to properly break down GAGs causes them to build up in the lysosomes.
Signs and symptoms of MPS VII generally become more severe. Hip dysplasia and worsening pulmonary function are two of the progressive symptoms commonly observed in patients with MPS VII. In some cases, people with MPS VII may develop new signs and symptoms, which may also progress. It is important to recognize the signs and symptoms of MPS VII. Early and accurate diagnosis and management may help to slow disease progression.
read more
Related Content
-
COVID-19 and MPS Patientshttps://www.youtube.com/watch?v=euwZ_vDW...
-
Progression of Cardiovascular Manifestations in Adults and Children With Mucopolysaccharidoses With and Without Enzy...Cardiovascular involvement is among the ...
-
Airway Management of the Deformed Trachea Using T-Tube Stents in Patients With Mucopolysaccharidosis Type IVAIntroduction: Mucopolysaccharidosis (MPS...
-
New Type A ERT Candidate on Track for Clinical TrialJapanese company, JCR Pharmaceuticals, h...
-
Oral Treatment for Mucopolysaccharidosis VI: Outcomes of the First Phase Iia Study With OdiparcilMucopolysaccharidosis (MPS) disorders ar...
-
AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for AVR-RD-05, a Gene Therapy for Mucopolysacc...AVROBIO, Inc., a leading clinical-stage ...
-
iPS-Derived Neural Stem Cells for Disease Modeling and Evaluation of Therapeutics for Mucopolysaccharidosis Type IIMucopolysaccharidosis type II (MPS II), ...